andrewkaretas, Author at Allogene

Bob T.

Post author:andrewkaretas
Post published:September 29, 2021
Post category:reasons

“I was eager to join Allogene for the people and the science. I get to work with intelligent, driven colleagues while studying the “crazy” science of treating recipient patients with…

Ben B.

Post author:andrewkaretas
Post published:September 29, 2021
Post category:reasons

“So no one has to wait for a cure.” — Ben B.

Alice C.

Post author:andrewkaretas
Post published:September 29, 2021
Post category:reasons

“To find satisfaction in striving towards a collective purpose, to face the challenges of scientific innovation for improving (and saving) lives of fellow human beings.“ — Alice C.

Developing Life-Changing Treatments for Blood Cancer

Post author:andrewkaretas
Post published:September 8, 2021
Post category:Perspectives

Read more about the article Safety and PK/PD of ALLO-647, an Anti-CD52 Antibody, With Fludarabine (Flu)/Cyclophosphamide (Cy) for Lymphodepletion in Allogeneic CAR T Cell Therapy

Safety and PK/PD of ALLO-647, an Anti-CD52 Antibody, With Fludarabine (Flu)/Cyclophosphamide (Cy) for Lymphodepletion in Allogeneic CAR T Cell Therapy

Post author:andrewkaretas
Post published:June 18, 2021
Post category:ALLO-647 Scientific Publications

$Read more about the article First-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study$

First-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study

Post author:andrewkaretas
Post published:June 1, 2021
Post category:CD19 Scientific Publications

@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Post author:andrewkaretas
Post published:May 19, 2021
Post category:Twitter

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

Post author:andrewkaretas
Post published:May 19, 2021
Post category:Latest News

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Post author:andrewkaretas
Post published:May 19, 2021
Post category:Twitter

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Post author:andrewkaretas
Post published:May 19, 2021
Post category:Twitter

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…

Bob T.

Ben B.

Alice C.

Developing Life-Changing Treatments for Blood Cancer

Safety and PK/PD of ALLO-647, an Anti-CD52 Antibody, With Fludarabine (Flu)/Cyclophosphamide (Cy) for Lymphodepletion in Allogeneic CAR T Cell Therapy

First-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study

@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

CONNECT

CONNECT